Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Brain-derived tau for monitoring brain injury in acute ischemic stroke

  • ESCAPE-NEXT biomarker substudy investigators
  • , DEMDAS study group
  • Ludwig-Maximilians-Universität
  • Eberhard Karls Universität Tübingen
  • University of Basel
  • Munich Cluster of Systems Neurology (SyNergy)
  • Sahlgrenska University Hospital/Östra
  • Charite - Universitatsmedizin Berlin
  • German Center for Mental Health (DZPG)
  • German Centre for Neurodegenerative Diseases (DZNE)
  • Otto-von-Guericke-Universität Magdeburg
  • Rheinische Friedrich-Wilhelms-Universität Bonn
  • Technische Universität München
  • Georg-August-Universität Göttingen
  • University of British Columbia
  • Universitätsklinikum Würzburg
  • Sunnybrook and Women's College Health Sciences Centre
  • Hospital Altenburger Land GmbH
  • St Michael's Hospital
  • Klinikum Augsburg
  • Universitätsklinikum Carl Gustav Carus
  • University of Manitoba
  • University of Oslo
  • University of Western Ontario
  • Universität Witten/Herdecke
  • Ruprecht-Karls-Universität Heidelberg
  • Rheinisch-Westfälische Technische Hochschule Aachen
  • Department of Medicine
  • Cumming School of Medicine
  • NoNO Inc.
  • Hotchkiss Brain Institute

Abstract

A specific and accurate blood test for acute brain injury could help monitor infarct growth in ischemic stroke and serve as a surrogate end point in clinical trials. Using a single-molecule detection assay, we assessed plasma brain-derived tau (BD-tau), a marker selectively quantifying tau protein from the central nervous system, in a prospective cohort of 502 patients with acute ischemic stroke with serial blood sampling from admission to day 7. Higher BD-tau concentrations at admission were associated with more extensive early brain injury on computed tomography and predicted larger final infarct volumes. BD-tau increases from admission to day 2 were related to infarct growth. BD-tau concentrations rose until day 7 and were higher in patients with secondary events, including recurrent stroke. After thrombectomy, the rise of BD-tau was smaller in patients with complete versus incomplete recanalization. BD-tau outperformed other blood markers and imaging metrics in predicting 90-day functional outcome across infarct size strata and time points. In an independent multicenter prospective cohort (N = 519), BD-tau showed higher performance than magnetic resonance imaging–derived final infarct volume in predicting functional outcomes at 3, 12, and 36 months. In the biomarker substudy of a phase 3 trial assessing nerinetide in patients with ischemic stroke (N = 193), BD-tau showed predictive performance comparable to the other cohorts, mediated the relationship between recanalization and functional outcome, and showed a 49% smaller increase in the nerinetide group versus placebo. Overall, plasma BD-tau tracked ischemic brain injury over time, outperformed other biomarkers in predicting functional outcomes, and identified possible treatment responses.

OriginalspracheEnglisch
Aufsatznummereadz1280
ZeitschriftScience Translational Medicine
Jahrgang18
Ausgabenummer832
Seiten (von - bis)eadz1280
ISSN1946-6234
DOIs
PublikationsstatusVeröffentlicht - 14.01.2026

Fördermittel

for consultant services, grants from Medtronic, compensation from Mentice for consultant services, compensation from Philips for consultant services, grants from Johnson & Johnson health care Systems inc., and compensation from Medtronic for consultant services. r.h.S. reports compensation from Sunnybrook research institute for other services, stock holdings in Follow Md inc., and compensation from F. hoffmann-la roche for consultant services. M.T. reports stock options in nono inc., stock holdings in nono inc., and employment by nono inc. M.d.h. reports grants from canadian institutes of health research, grants from Boehringer ingelheim, grants from nono inc., compensation from Brainsgate ltd. for consultant services, stock options in Basking Bioscience llc, employment by the University of calgary, and grants from Medtronic. S.T. reports compensation from Quanterix for consultant services. M.e. reports grants from Bayer and ipsen and fees paid to the charité from amgen, astraZeneca, Bayer, BMS, and daiichi Sankyo; all outside the submitted work. a.h.a. reports unrestricted research grants from Boehringer ingelheim; honoraria for lectures from BMS and Pfizer, Teva, abbvie, lundbeck, and novartis; and participation in advisory boards for lundbeck and abbvie; not any of these are related to this paper. n.V., n.l.K., M. dichgans, and S.T. report a patent on the use of Bd-tau (PcT/eP2024/075417). no other potential competing interests were reported. Data, code, and materials availability: deidentified raw data on Bd-tau concentrations and primary end points (infarct volume, clinical severity, and functional outcome) from the three cohorts included in this study have been deposited in harvard dataverse and are available at doi: https://doi.org/10.7910/dVn/dF1ehn. Acknowledgments: We would like to thank the participating patients, families, and investigators from all studies. Funding: This work was supported by corona Foundation grant S199/10081/2020 (to S.T.); canadian institutes of health research grant PJT-180434 (to M.d.h.); ludwig Maximilian Universität grant FöFole 1216/1176 (to n.V.); the German research Foundation, Walter Benjamin Program project no. 540798028 (to n.V.); leducq Foundation grant 21cVd04 (to S.T.); German Federal Ministry of education and research, european Joint Program for rare diseases grant eJPrd23-010 (to S.T.); ludwig Maximilian Universität, grants lMUexcellent nFF-1507 and Medical & clinician Scientist Program acS-16 (to S.T.); the Munich cluster for Systems neurology (eXc 2145 Synergy, id 390857198); German center for neurodegenerative diseases (dZne), Vascular dementia research Foundation, leducq Foundation grant 22cVd01 (to M. dichgans); Friedrich-Baur-Stiftung 52/23 (to S.T.); the dFG We would like to thank the participating patients, families, and investigators from all studies. This work was supported by corona Foundation grant S199/10081/2020 (to S.T.); canadian institutes of health research grant PJT-180434 (to M.d.h.); ludwig Maximilian Universität grant FöFole 1216/1176 (to n.V.); the German research Foundation, Walter Benjamin Program project no. 540798028 (to n.V.); leducq Foundation grant 21cVd04 (to S.T.); German Federal Ministry of education and research, european Joint Program for rare diseases grant eJPrd23-010 (to S.T.); ludwig Maximilian Universität, grants lMUexcellent nFF-1507 and Medical & clinician Scientist Program acS-16 (to S.T.); the Munich cluster for Systems neurology (eXc 2145 Synergy, id 390857198); German center for neurodegenerative diseases (dZne), Vascular dementia research Foundation, leducq Foundation grant 22cVd01 (to M. dichgans); Friedrich-Baur-Stiftung 52/23 (to S.T.); the dFG under Germany’s excellence Strategy (eXc-2049-390688087; to M.e.); collaborative research center reTune Trr 295-424778381 (to M.e.); and clinical research Group KFo 5023 BecaUSe-Y project 2 en343/16-1 (to M.e.).

TrägerTrägernummer
Medtronic
University of Calgary
Munich Cluster for Systems Neurology390857198
Fondation Leducq21cVd04
Corona-StiftungPJT-180434, S199/10081/2020
Bundesministerium für Forschung, Technologie und RaumfahrtlMUexcellent nFF-1507
Friedrich‐Baur‐Stiftung2 en343/16-1
Stiftung zur Erforschung der Vaskulären Demenz22cVd01
Deutsche Forschungsgemeinschaft540798028
Ludwig-Maximilians-Universität1216/1176

    UN SDGs

    Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

    1. SDG 3 – Gesundheit und Wohlergehen
      SDG 3 – Gesundheit und Wohlergehen

    DFG-Fachsystematik

    • 2.23-07 Klinische Neurologie, Neurochirurgie und Neuroradiologie

    Fingerprint

    Untersuchen Sie die Forschungsthemen von „Brain-derived tau for monitoring brain injury in acute ischemic stroke“. Zusammen bilden sie einen einzigartigen Fingerprint.

    Dieses zitieren